Is Personalis, Inc. (PSNL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 6.4% / 30% | 26.6% / 30% | 1.2% / 30% | 6.51% / 5% | ✗ NOT HALAL |
| DJIM | 6.4% / 33% | 26.6% / 33% | 1.2% / 33% | 6.51% / 5% | ✗ NOT HALAL |
| MSCI | 16.4% / 33% | 68.5% / 33% | 3.0% / 33% | 6.51% / 5% | ✗ NOT HALAL |
| S&P | 6.4% / 33% | 26.6% / 33% | 1.2% / 33% | 6.51% / 5% | ✗ NOT HALAL |
| FTSE | 16.4% / 33% | 68.5% / 33% | 3.0% / 50% | 6.51% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 22.7% | |
| Operating Margin | -145.7% | |
| Net Margin | -116.7% | |
| Return on Equity (ROE) | -35.0% | |
| Return on Assets (ROA) | -18.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$75M |
| Free Cash Flow | -$79M |
| Total Debt | $40M |
| Debt-to-Equity | 16.9 |
| Current Ratio | 6.8 |
| Total Assets | $334M |
Price & Trading
| Last Close | $7.32 |
| 50-Day MA | $8.50 |
| 200-Day MA | $7.54 |
| Avg Volume | 1.3M |
| Beta | 2.1 |
|
52-Week Range
$2.83
| |
About Personalis, Inc. (PSNL)
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Personalis, Inc. (PSNL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Personalis, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Personalis, Inc.'s debt ratio?
Personalis, Inc.'s debt ratio is 6.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 16.4%.
What are Personalis, Inc.'s key financial metrics?
Personalis, Inc. has a market capitalization of $663M, and revenue of $70M. The company maintains a gross margin of 22.7% and a net margin of -116.7%. Return on equity stands at -35.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.